News | May 25, 2021
Bal Pharma launches BALflu, Favipiravir formulation in India
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
SNV4818, the oral drug, is pan-mutant–selective PI3K? inhibitor aimed at treating HR+/HER2- breast cancer and potentially other solid tumors
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
Pfizer recommends that shareholders do not tender their shares in response to Tutanota’s offer
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio
Subscribe To Our Newsletter & Stay Updated
